JOP20200126B1 - طرق استخدام وتركيبات تحتوي على دولاجلوتيد - Google Patents

طرق استخدام وتركيبات تحتوي على دولاجلوتيد

Info

Publication number
JOP20200126B1
JOP20200126B1 JOJO/P/2020/0126A JOP20200126A JOP20200126B1 JO P20200126 B1 JOP20200126 B1 JO P20200126B1 JO P20200126 A JOP20200126 A JO P20200126A JO P20200126 B1 JOP20200126 B1 JO P20200126B1
Authority
JO
Jordan
Prior art keywords
methods
formulations containing
dulaglutide
containing dulaglutide
doses
Prior art date
Application number
JOJO/P/2020/0126A
Other languages
Arabic (ar)
English (en)
Inventor
Lai San Tham
David Andrew Cox
Zvonko Milicevic
David Bradley Woodward
Andrew Gordon Werner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200126(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20200126A1 publication Critical patent/JOP20200126A1/ar
Application granted granted Critical
Publication of JOP20200126B1 publication Critical patent/JOP20200126B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
JOJO/P/2020/0126A 2017-11-21 2020-05-21 طرق استخدام وتركيبات تحتوي على دولاجلوتيد JOP20200126B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Publications (2)

Publication Number Publication Date
JOP20200126A1 JOP20200126A1 (ar) 2020-05-21
JOP20200126B1 true JOP20200126B1 (ar) 2024-04-18

Family

ID=64572530

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2020/0126A JOP20200126B1 (ar) 2017-11-21 2020-05-21 طرق استخدام وتركيبات تحتوي على دولاجلوتيد

Country Status (21)

Country Link
US (2) US11576950B2 (https=)
EP (1) EP3713593A2 (https=)
JP (3) JP7221956B2 (https=)
KR (2) KR20220146656A (https=)
CN (2) CN120478602A (https=)
AU (2) AU2018372709B2 (https=)
BR (1) BR112020007817A2 (https=)
CL (1) CL2020001252A1 (https=)
CR (1) CR20200202A (https=)
DO (1) DOP2020000104A (https=)
EA (1) EA202090971A1 (https=)
EC (1) ECSP20026436A (https=)
IL (1) IL274563B2 (https=)
JO (1) JOP20200126B1 (https=)
MA (1) MA50798A (https=)
MX (1) MX2020005231A (https=)
PE (1) PE20200847A1 (https=)
PH (1) PH12020550795A1 (https=)
SG (1) SG11202003687RA (https=)
UA (1) UA127588C2 (https=)
WO (1) WO2019103875A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
MX2022009383A (es) * 2020-01-30 2022-11-07 Lilly Co Eli Usos terapéuticos de dulaglutida.
JP2023525898A (ja) * 2020-05-19 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
CN117915939A (zh) 2021-06-23 2024-04-19 伊莱利利公司 肠降血糖素类似物用于血糖控制和体重管理

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
CN101730523A (zh) * 2007-07-10 2010-06-09 伊莱利利公司 GLP-1-Fc融合蛋白质制剂
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
JP7191043B2 (ja) 2017-06-01 2022-12-16 イーライ リリー アンド カンパニー 慢性腎疾患の治療のためのデュラグルチド

Also Published As

Publication number Publication date
EP3713593A2 (en) 2020-09-30
UA127588C2 (uk) 2023-10-25
JOP20200126A1 (ar) 2020-05-21
JP7818412B2 (ja) 2026-02-20
CR20200202A (es) 2020-08-20
US11576950B2 (en) 2023-02-14
KR20220146656A (ko) 2022-11-01
IL274563A (en) 2020-06-30
CL2020001252A1 (es) 2020-10-30
IL274563B1 (en) 2023-08-01
AU2022203372A1 (en) 2022-06-09
SG11202003687RA (en) 2020-06-29
CN111356472A (zh) 2020-06-30
JP7221956B2 (ja) 2023-02-14
ECSP20026436A (es) 2020-06-30
MX2020005231A (es) 2020-08-24
PH12020550795A1 (en) 2021-04-19
IL274563B2 (en) 2023-12-01
KR102589234B1 (ko) 2023-10-16
AU2022203372B2 (en) 2025-04-10
NZ763815A (en) 2023-11-24
US20240189394A1 (en) 2024-06-13
MA50798A (fr) 2020-09-30
JP2024056908A (ja) 2024-04-23
AU2018372709A1 (en) 2020-05-14
CN120478602A (zh) 2025-08-15
BR112020007817A2 (pt) 2020-10-06
JP2021502379A (ja) 2021-01-28
WO2019103875A3 (en) 2019-07-25
US20200330558A1 (en) 2020-10-22
JP2022062153A (ja) 2022-04-19
WO2019103875A2 (en) 2019-05-31
EA202090971A1 (ru) 2020-08-07
DOP2020000104A (es) 2020-08-31
CA3082625A1 (en) 2019-05-31
AU2018372709B2 (en) 2022-04-28
KR20200076705A (ko) 2020-06-29
PE20200847A1 (es) 2020-08-18

Similar Documents

Publication Publication Date Title
PH12020551397A1 (en) Cot modulators and methods of use thereof
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MX378273B (es) Compuestos activos hacia bromodominios.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
EP3735976A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790273A1 (ru) Флагеллиновые композиции и их применение
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
CL2015002897A1 (es) Inhibidores de bace1
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MX391757B (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
EA202090270A1 (ru) Новые замещенные производные ксантина
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX2022010827A (es) Composiciones de microesferas de gas encapsulado en lipidos y metodos relacionados.
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
MX2020003763A (es) Composiciones de flumioxazina y metodos para usar las mismas.
MX390441B (es) Formulaciones liquidas de fosfaplatino.
PH12018501166B1 (en) Concentrated gibberellin solution formulations
MX383460B (es) Derivados peptidicos novedosos y sus usos.
EA201792093A1 (ru) 2-тиопиримидиноны
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении